Clinical trials: Immunity, Cellular
Pertussis
Gambia Pertussis Study (GaPs)
Currently, there are two types of vaccines available against pertussis (whooping cough), an infectious disease of the respiratory tract that can be extremely serious in very young children.
- Trial name
- GaPs (NCT03606096)
- Testing
- Boostrix IPV infant acellular Pertussis, Boostrix IPV infant whole Pertussis, TT infant acellular Pertussis
- Where
- The Gambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Respiratory Syncytial Virus Infections, Influenza, Human
Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory viruses including influenza and respiratory syncytial virus (RSV) are among the most important causes of severe disease globally, infecting everyone repeatedly throughout life.
- Trial name
- NCT02755948
- Testing
- RSV A Memphis 37, Influenza A/California/04/2009-likw (H1N1), Influenza A/Belgium/4217/2015 (H3N2)
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Haematological Malignancies
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.
- Trial name
- ICAT (NCT01827579)
- Testing
- CD25/71 allodepleted donor T-cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- University College, London
Transplantation, Hematopoietic Stem Cell
Monitoring of Measles-specific Immune Status in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients
Measles, a highly contagious disease, is potentially serious in adult allogenic hematopoietic stem cell transplant (allo-HSCT) recipients.
- Trial name
- MaRROwVacc (NCT05947864)
- Testing
- Biological samples (blood and oral fluid)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
COVID-19, Coronavirus Infections
Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older
The goal of this clinical trial is to assess the immunogenicity, efficacy and safety of the Convacell vaccine in healthy adult volunteers aged 18 years and older.
- Conditions
- COVID-19, Coronavirus Infections, Respiratory Tract Infections, COVID-19 Respiratory Infection
- Trial name
- NCT05726084
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 6 sites in Russia
- Volunteers
- 16,304 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Shingles
Optimal Timing of Zoster Vaccine After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
- Trial name
- NCT02704572
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Idiopathic CD4 T Cell Lymphocytopenia
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
Background: Diseases related to human papillomavirus (HPV) include warts, lesions, and cancers. ICL is idiopathic CD4 T cell lymphocytopenia. People with this rare disease get more HPV-related diseases than other people do.
- Trial name
- NCT03519464
- Testing
- Gardasil 9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neoplasms
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
According to a survey from Department of Health in 2004, cancer has been the leading cause of death in the Taiwan area. In 2004, people died of cancer, accounting for 27.2 percent of all deaths.
- Trial name
- NCT00521287
- Testing
- Immune profiling and DC vaccine
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Metabolism Disorder, Cancer
Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )
Recent EMA and FDA approvals have made immune checkpoint inhibitors (ICI) a standard of care in cancer treatment. ICI, used alone or as a combination are now the backbone of renal cell and lung carcinoma treatment.
- Conditions
- Metabolism Disorder, Cancer, Immune Checkpoint Inhibitors
- Trial name
- RIMEC (NCT04808817)
- Testing
- calorimetry, impedance measurement at baseline and after 3 months of treatment
- Where
- 2 sites in France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Meningococcal Infections
Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Meningitis or septicaemia (blood poisoning) caused by group B meningococcal infection (MenB) is an important cause of death and disability in the UK. Prevention through vaccination therefore remains a key public health priority.
- Trial name
- NCT00774384
- Testing
- NZ MenB OMV vaccine (NZ98/254)
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Cytomegalovirus Infections
Cytomegalovirus Cell-Mediated Immunity
Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems.
- Trial name
- NCT00815165
- Where
- 2 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 1
The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)
The Diabetes Prevention Trial of Type 1 (DPT-1) was a multicenter randomized, controlled clinical trial designed to determine whether it is possible to delay or prevent the clinical onset of type 1 diabetes through daily doses of…
- Trial name
- DPT-1 (NCT00004984)
- Testing
- Parenteral Insulin, Close Observation, Oral Insulin
- Where
- 15 sites in United States, Canada
- Volunteers
- 711 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Allergic Rhinitis, Asthma
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
The investigators propose the development of a range of nasal spray challenge models to study the way the nose can respond to different types of nasal challenge that elicit different forms of inflammation.
- Conditions
- Allergic Rhinitis, Asthma, Latent Tuberculosis
- Trial name
- NCT02090374
- Testing
- Poly ICLC, Poly I:C, R848
- Where
- United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure
Shingrix in Renal Transplant Recipients
The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant.
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation
- Trial name
- NCT04128189
- Testing
- Shingrix
- Where
- 4 sites in United States
- Volunteers
- 132 people
- Sponsor
- University of Colorado, Denver
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot phase II trial studies the effect of pembrolizumab with or without carboplatin and paclitaxel on immune response in patients with non-small cell lung cancer that has come back or stage IIIB-IV.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02581943
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wake Forest University Health Sciences
Sickle Cell Disease
Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD
Sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will probably preserve their immune response to vaccinations administered prior to the…
- Trial name
- PROTECT (NCT05200338)
- Testing
- Engerix-B
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cryoglobulinemia Vasculitis
Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients
A systemic Vasculitis is found in 5 to 10% of HCV infected patients with mixed cryoglobulinemia (MC). It mainly involves the skin, peripheral nerve and the kidney and may be life threatening.
- Trial name
- NCT00574652
- Testing
- Proleukin
- Where
- France
- Volunteers
- 10 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Colon Cancer, Peritoneal Carcinoma
Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers
Colorectal cancer (CRC) is the 3rd most common cancer in France. Treatment of CRC relies primarily on surgical removal of the primary tumor and chemotherapy is the current standard of care for synchronous metastatic disease.
- Trial name
- I-COMET (NCT06435689)
- Testing
- Sampling
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sars-CoV2, Innate Immunity
Immune Cells Phenotypes During COVID-19
The ongoing pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) has infected more than one hundred twenty million peoples worldwide one year after its onset with a case-fatality rate of almost 2%.
- Conditions
- Sars-CoV2, Innate Immunity, Immunization; Infection, Alveolar Lung Disease
- Trial name
- IMMUNO-COVID (NCT04816760)
- Testing
- Peripheral blood samples
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Institut Hospitalo-Universitaire Méditerranée Infection